Exane Derivatives Ptc Therapeutics, Inc. Transaction History
Exane Derivatives
- $157 Million
- Q2 2022
A detailed history of Exane Derivatives transactions in Ptc Therapeutics, Inc. stock. As of the latest transaction made, Exane Derivatives holds 12 shares of PTCT stock, worth $543. This represents 0.0% of its overall portfolio holdings.
Number of Shares
12
Previous 128
90.63%
Holding current value
$543
Previous $4,000
100.0%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding PTCT
# of Institutions
299Shares Held
80.2MCall Options Held
223KPut Options Held
156K-
Vanguard Group Inc Valley Forge, PA8.85MShares$401 Million0.01% of portfolio
-
Black Rock Inc. New York, NY7.77MShares$352 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY7.48MShares$339 Million6.25% of portfolio
-
Armistice Capital, LLC New York, NY5.43MShares$246 Million4.22% of portfolio
-
Wellington Management Group LLP Boston, MA5.42MShares$245 Million0.05% of portfolio
About PTC THERAPEUTICS, INC.
- Ticker PTCT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 71,541,000
- Market Cap $3.24B
- Description
- PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on...